Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

Core Insights - Theravance Biopharma announced that the Phase 3 CYPRESS study of ampreloxetine did not meet its primary endpoint, leading to the decision to wind down the ampreloxetine program [1][9][10] Financial Position - The company expects to have approximately $400 million in cash at the end of Q1 2026, following the receipt of milestone payments from YUPELRI and TRELEGY [5][21] - Cash totaled $326.5 million as of Q4 2025, with no debt [12][21] - The company anticipates generating annualized cash flow of approximately $60 to $70 million starting in Q3 2026, driven by cost savings and sales from YUPELRI [4][8] Organizational Changes - Theravance Biopharma is implementing an organizational restructuring that will reduce operating expenses by approximately 60%, equating to about $70 million in savings [3][11] - The restructuring will impact approximately 50% of the workforce, including the complete wind-down of the R&D function and a significant reduction in G&A employees [11][3] Strategic Review - The Strategic Review Committee is accelerating its evaluation of alternatives to maximize shareholder value, including the potential sale of the company [2][8] - The committee has been working with Lazard to explore various strategic options since its formation in 2024 [2][8] Product Focus - The company is streamlining its portfolio to focus on YUPELRI, which is expected to generate durable cash flow and has long-dated intellectual property protection in the U.S. until 2039 [7][12] - YUPELRI achieved net sales of $266.6 million in FY 2025, representing a 12% year-over-year increase [13]